Form 8-K

8-K — Scholar Rock Holding Corp

Accession: 0001104659-26-037350

Filed: 2026-03-31

Period: 2026-03-31

CIK: 0001727196

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Regulation FD Disclosure

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — tm2610664d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2610664d1_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2610664d1_8k.htm · Sequence: 1

false

0001727196

2026-03-31

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of earliest event Reported): March 31, 2026

Scholar Rock Holding Corporation

(Exact Name of Registrant as Specified in Charter)

Delaware

001-38501

82-3750435

(State or Other Jurisdiction of

Incorporation)

(Commission File Number)

(I.R.S. Employer Identification Number)

301 Binney Street, 3rd Floor, Cambridge, MA 02142

(Address of Principal Executive Offices) (Zip Code)

(857) 259-3860

(Registrant's telephone

number, including area code)

(Former name or

former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.001 per share

SRRK

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as

defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17

CFR §240.12b-2). Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected

not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ¨

Item 7.01. Regulation FD Disclosure.

On March 31, 2026, Scholar Rock Holding Corporation

(the “Company”) issued a press release announcing it resubmitted its biologics license application (“BLA”) to

the U.S. Food and Drug Administration (the “FDA”) for apitegromab for the treatment of children and adults with spinal muscular

atrophy (“SMA”). A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K. The Company will

hold a conference call scheduled for 8:00 am ET on March 31, 2026 to discuss this update.

The information in this Report on Form 8-K and

Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the

Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section,

nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except

as expressly set forth by specific reference in such filing.

Item 8.01. Other Events.

On March 31, 2026, the Company announced that

it resubmitted its BLA to the FDA for apitegromab for the treatment of children and adults with SMA. The Company anticipates FDA

acceptance within 30 days and a review period of up to six months from the date of resubmission, with a Prescription Drug User Fee

Act (“PDUFA”) action date expected in late September 2026.

Cautionary Notes on Forward-Looking Statements

This Current Report on Form 8-K contains “forward-looking

statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended,

and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected

future business and financial performance and financial condition, and often contain words such as “anticipate,” “believe,”

“expect,” “intend,” “plan,” “seek,” “see,” “will,” “would,”

“may,” “target,” and similar expressions and variations or negatives of these words. Forward-looking statements

by their nature address matters that are, to different degrees, uncertain, such as statements regarding timing of any regulatory submissions

and anticipated approvals, the therapeutic potential, clinical benefits and safety of any product candidates, the Company’s ability

to address the observations identified in the complete response letter, expectations regarding resubmission and timing of its BLA for

apitegromab upon the successful FDA reinspection of Catalent Indiana, expectations regarding commercial launch timing in the U.S. and

in Europe, expectations regarding a new fill finish facility and the achievement of important milestones, and the potential of its product

candidates and proprietary platform. These and other forward-looking statements are not guarantees of future results and are subject to

risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking

statements. Important risk factors that may cause such a difference include, but are not limited to the risks described in the Company’s

most recent annual report on Form 10-K for the year ended December 31, 2025. We undertake no obligation to update any forward-looking

statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date

hereof. The provision of the information in this report shall not be deemed an admission as to the materiality of any of the information

contained herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No.

Description

99.1

Press Release issued by the Company on March 31, 2026, furnished hereto.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934,

the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Scholar Rock Holding Corporation

Date: March 31, 2026

By:

/s/ Junlin Ho

Junlin Ho

General Counsel & Corporate Secretary

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2610664d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Scholar Rock Resubmits Biologics License Application

(BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

· Apitegromab BLA resubmission includes Catalent Indiana LLC (part of Novo Nordisk) and second U.S.-based fill-finish facility, aligned

with FDA guidance from March 3, 2026 Type C meeting

· FDA and Novo Nordisk Q1 2026 interactions resulted in Scholar Rock’s alignment with FDA to resubmit apitegromab BLA prior

to FDA reinspection of Catalent Indiana facility

· FDA and Scholar Rock Q1 2026 interactions regarding accelerated progress in qualifying a second fill-finish facility resulted in

alignment with FDA to include facility in BLA resubmission

· Company anticipates FDA acceptance of BLA within 30 days and a review period of up to 6 months from date of resubmission, with

PDUFA action date expected in late September 2026

· Management to host a conference call today at 8:00am ET

CAMBRIDGE, Mass.—(BUSINESS WIRE)—March 31, 2026-- Scholar

Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy

(SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance

musculoskeletal health, today announced it has resubmitted the Biologics License Application (BLA) for apitegromab for the treatment of

children and adults with SMA to the U.S. Food and Drug Administration (FDA).

Apitegromab is the first

and only muscle-targeted therapy to demonstrate statistically significant and clinically meaningful improvements in motor function in

a pivotal Phase 3 clinical trial in patients with SMA receiving treatment with an SMN-targeted therapy.

“Our apitegromab BLA resubmission marks an important step forward

in our mission to bring the world’s first muscle-targeted therapy to children and adults living with SMA,” said David L. Hallal,

Chairman and Chief Executive Officer of Scholar Rock. “We continue to be encouraged by the FDA’s engagement and shared sense

of urgency as we work relentlessly for the SMA community. As we execute our plans for both Catalent Indiana and our second fill-finish

facility, we look forward to anticipated apitegromab approvals and launches in both the U.S. and Europe this year.”

In September 2025, Scholar Rock

received a Complete Response Letter (CRL) from the FDA for apitegromab related to observations identified during a routine general site

inspection of Catalent Indiana, LLC (part of Novo Nordisk). The observations were not specific to apitegromab and the CRL did not cite

any other approvability concerns.

Since that time, Scholar Rock, Catalent Indiana, and the FDA have engaged

in several constructive and collaborative interactions, including an in-person Type A meeting in November 2025 and a meeting between Catalent

Indiana and the FDA early in the first quarter of 2026. During the meeting and an FDA site visit that followed, no additional corrective

actions were requested by the FDA to Novo Nordisk’s remediation plan. The decision to resubmit the apitegromab BLA prior to FDA

reinspection of Catalent Indiana was made in alignment with the FDA.

The apitegromab BLA resubmission also includes a second U.S.-based

fill-finish facility to strengthen the apitegromab supply chain and support future growing demand across the planned global commercial

footprint. Following a positive Type C meeting on March 3, 2026, Scholar Rock aligned with the FDA to include the additional facility

in the BLA resubmission based on the Company’s accelerated commercial fill-finish timelines.

Scholar Rock anticipates FDA acceptance of the BLA within 30 days of

resubmission and a review period of up to six months from the date of resubmission. A PDUFA action date is expected in late September

2026.

Updates to the apitegromab

BLA for the resubmission were limited in scope and primarily composed of a standard

safety update.

In Europe, the European Medicines Agency (EMA) review of the Marketing

Authorisation Application (MAA) for apitegromab is progressing well, with a decision anticipated mid-2026.

The FDA has granted Fast Track, Orphan Drug, Priority Review, and Rare

Pediatric Disease designations to apitegromab for the treatment of SMA. The European Medicines Agency (EMA) has granted Priority

Medicines (PRIME) and Orphan Medicinal Product designations.

Conference Call Information

Scholar Rock will host a conference call and webcast today, Tuesday,

March 31, at 8:00 a.m. ET. To access the live audio webcast, please go to “Events and Presentations” in the Investors

section of the Scholar Rock website at http://investors.scholarrock.com.

To participate via telephone, please register in advance here.

Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call. A replay of

the webcast will be available on the Company’s website for approximately 90 days.

About Apitegromab

Apitegromab is an investigational fully

human monoclonal antibody inhibiting myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal

muscle. It is the first muscle-targeted treatment candidate in spinal muscular atrophy (SMA) to demonstrate clinical success in a pivotal

Phase 3 clinical trial. Myostatin, a member of the TGFβ superfamily of growth factors, is expressed primarily by skeletal muscle

cells, and the absence of its gene is associated with an increase in muscle mass and strength in multiple animal species, including humans.

Scholar Rock believes that its highly selective targeting of pro- and latent forms of myostatin with apitegromab may lead to a clinically

meaningful improvement in motor function in patients with SMA. The U.S. Food and Drug Administration (FDA) has granted Fast Track, Orphan

Drug and Rare Pediatric Disease designations, and the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) and Orphan

Medicinal Product designations, to apitegromab for the treatment of SMA. Apitegromab has not been approved for any use by the FDA or

any other regulatory agency.

About Scholar Rock

Scholar Rock is a late-stage biopharmaceutical company focused

on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other rare, severe, and

debilitating neuromuscular diseases. As a global leader in myostatin biology, a field focused on proteins that regulate muscle mass,

the biopharmaceutical company is named for the visual resemblance of a scholar rock to protein structures. Our commitment to unlock fundamentally

different treatment approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies

to modulate protein growth factors with extraordinary selectivity. Scholar Rock works every day to create new possibilities

for patients through its highly innovative anti-myostatin program, including opportunities in additional rare neuromuscular diseases.

Learn more at ScholarRock.com and follow @ScholarRock on X and on LinkedIn.

Scholar Rock® is a registered trademark of Scholar

Rock, Inc.

Availability of Other Information About Scholar Rock

Investors and others should note that we communicate with our investors

and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures,

investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts

and webcast transcripts, as well as on X (formerly known as Twitter) and LinkedIn. The information that we post on our website or on

X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review

the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by

reference in any filing under the Securities Act of 1933, as amended.

Forward-Looking Statements

This press release contains "forward-looking statements"

within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar

Rock’s future expectations, plans and prospects, including without limitation, Scholar Rock’s timing of any regulatory submissions

and anticipated approvals, the therapeutic potential, clinical benefits and safety of any product candidates, its ability to address the

observations identified in the complete response letter, expectations regarding resubmission and timing of review of its BLA for apitegromab,

expectations regarding approval and commercial launch timing in the U.S. and in Europe, expectations regarding a new fill-finish facility

and the achievement of important milestones, and the potential of its product candidates and proprietary platform. The use of words such

as “may,” “might,” “could,” “will,” “should,” “expect,” “plan,”

“anticipate,” “believe,” “estimate,” “project,” “intend,” “future,”

“potential,” or “continue,” and other similar expressions are intended to identify such forward-looking statements.

All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks

and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking

statements. These risks and uncertainties include, without limitation, whether preclinical and clinical data, including the results from

the Phase 3 SAPPHIRE trial, will be sufficient to support regulatory approval, that preclinical and clinical data, including the results

from the Phase 2 or Phase 3 clinical trial of apitegromab, or the preclinical data for SRK-439, are not predictive of, may be inconsistent

with, or more favorable than, data generated from future or ongoing clinical trials of the same product candidates; whether the FDA will

accept the remediations to the Catalent Indiana fill-finish facility in response to the FDA observations, and whether the updated BLA

will be sufficient to support regulatory approval, risks related to delays in obtaining or failure to obtain FDA clearances or approvals

and noncompliance with FDA regulations, information provided or decisions made by regulatory authorities; and Scholar Rock’s dependence

on third parties for development and manufacture of product candidates including, without limitation, to supply any clinical trials as

well as those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock’s Annual Report on Form

10-K for the year ended December 31, 2025, as well as discussions of potential risks, uncertainties, and other important factors in Scholar

Rock’s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock’s

views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press

release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law.

Investor Contact

Laura Ekas, Ph.D.

ir@scholarrock.com

917-439-0374

Media Contact

Molly MacLeod, Ph.D.

media@scholarrock.com

802-579-5995

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Mar. 31, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Mar. 31, 2026

Entity File Number

001-38501

Entity Registrant Name

Scholar Rock Holding Corporation

Entity Central Index Key

0001727196

Entity Tax Identification Number

82-3750435

Entity Incorporation, State or Country Code

Entity Address, Address Line One

301 Binney Street

Entity Address, Address Line Two

3rd Floor

Entity Address, City or Town

Cambridge

Entity Address, State or Province

Entity Address, Postal Zip Code

02142

City Area Code

857

Local Phone Number

259-3860

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.001 per share

Trading Symbol

SRRK

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration